cagrilintide novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Trial Scorecard: REDEFINE 1 and
Trial Scorecard: REDEFINE 1 and 2 Novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results Company Business News Cagrilintide 10mg Prime Lab Peptides Healthy Returns: What's next for Novo Nordisk's obesity drug CagriSema
Pay in 4 interest-free payments of $6.24 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13


